Imperial College London

DrDagfinnAune

Faculty of MedicineSchool of Public Health

Research Associate
 
 
 
//

Contact

 

+44 (0)20 7594 8478d.aune

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Sen:2019:10.1002/ijc.31634,
author = {Sen, A and Papadimitriou, N and Lagiou, P and Perez-Cornago, A and Travis, RC and Key, TJ and Murphy, N and Gunter, M and Freisling, H and Tzoulaki, I and Muller, DC and Cross, AJ and Lopez, DS and Bergmann, M and Boeing, H and Bamia, C and Kotanidou, A and Karakatsani, A and Tjønneland, A and Kyrø, C and Outzen, M and Redondo, M-L and Cayssials, V and Chirlaque, M-D and Barricarte, A and Sánchez, M-J and Larrañaga, N and Tumino, R and Grioni, S and Palli, D and Caini, S and Sacerdote, C and Bueno-de-Mesquita, B and Kühn, T and Kaaks, R and Nilsson, LM and Landberg, R and Wallström, P and Drake, I and Bech, BH and Overvad, K and Aune, D and Khaw, K-T and Riboli, E and Trichopoulos, D and Trichopoulou, A and Tsilidis, KK},
doi = {10.1002/ijc.31634},
journal = {International Journal of Cancer},
pages = {240--250},
title = {Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition},
url = {http://dx.doi.org/10.1002/ijc.31634},
volume = {144},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The epidemiological evidence regarding the association of coffee and tea consumption with prostate cancer risk is inconclusive, and few cohort studies have assessed these associations by disease stage and grade. We examined the associations of coffee (total, caffeinated and decaffeinated) and tea intake with prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition. Among 142,196 men, 7,036 incident prostate cancer cases were diagnosed over 14 years of follow-up. Data on coffee and tea consumption were collected through validated country-specific food questionnaires at baseline. We used Cox proportional hazards regression models to compute hazard ratios (HRs) and 95% confidence intervals (CI). Models were stratified by center and age, and adjusted for anthropometric, lifestyle and dietary factors. Median coffee and tea intake were 375 mL/day and 106 mL/day, respectively, but large variations existed by country. Comparing the highest (median of 855 mL/day) versus lowest (median of 103 mL/day) consumers of coffee and tea (450 mL/day versus 12 mL/day) the HRs were 1.02 (95% CI, 0.94-1.09) and 0.98 (95% CI, 0.90-1.07) for risk of total prostate cancer, and 0.97 (95% CI, 0.79-1.21) and 0.89 (95% CI, 0.70-1.13) for risk of fatal disease, respectively. No evidence of association was seen for consumption of total, caffeinated or decaffeinated coffee or tea and risk of total prostate cancer or cancer by stage, grade or fatality in this large cohort. Further investigations are needed to clarify whether an association exists by different preparations or by concentrations and constituents of these beverages. This article is protected by copyright. All rights reserved.
AU - Sen,A
AU - Papadimitriou,N
AU - Lagiou,P
AU - Perez-Cornago,A
AU - Travis,RC
AU - Key,TJ
AU - Murphy,N
AU - Gunter,M
AU - Freisling,H
AU - Tzoulaki,I
AU - Muller,DC
AU - Cross,AJ
AU - Lopez,DS
AU - Bergmann,M
AU - Boeing,H
AU - Bamia,C
AU - Kotanidou,A
AU - Karakatsani,A
AU - Tjønneland,A
AU - Kyrø,C
AU - Outzen,M
AU - Redondo,M-L
AU - Cayssials,V
AU - Chirlaque,M-D
AU - Barricarte,A
AU - Sánchez,M-J
AU - Larrañaga,N
AU - Tumino,R
AU - Grioni,S
AU - Palli,D
AU - Caini,S
AU - Sacerdote,C
AU - Bueno-de-Mesquita,B
AU - Kühn,T
AU - Kaaks,R
AU - Nilsson,LM
AU - Landberg,R
AU - Wallström,P
AU - Drake,I
AU - Bech,BH
AU - Overvad,K
AU - Aune,D
AU - Khaw,K-T
AU - Riboli,E
AU - Trichopoulos,D
AU - Trichopoulou,A
AU - Tsilidis,KK
DO - 10.1002/ijc.31634
EP - 250
PY - 2019///
SN - 0020-7136
SP - 240
TI - Coffee and tea consumption and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition
T2 - International Journal of Cancer
UR - http://dx.doi.org/10.1002/ijc.31634
UR - https://www.ncbi.nlm.nih.gov/pubmed/29943826
UR - http://hdl.handle.net/10044/1/60439
VL - 144
ER -